Core Insights - Zentalis Pharmaceuticals is advancing the late-stage development of azenosertib, a first-in-class WEE1 inhibitor, as a biomarker-driven treatment for ovarian cancer, with significant milestones expected in 2026 [1][2]. Financial Performance - As of December 31, 2025, Zentalis reported cash, cash equivalents, and marketable securities totaling $245.9 million, providing a cash runway into late 2027 [5][11]. - Research and development expenses for the year ended December 31, 2025, were $107.3 million, a decrease from $167.8 million in 2024, primarily due to reductions in clinical expenses and personnel costs [11][15]. - General and administrative expenses decreased to $37.7 million in 2025 from $87.1 million in 2024, largely due to a reduction in personnel expenses [11][15]. Clinical Development Updates - The completion of enrollment for DENALI Part 2a is a key milestone, with topline results expected by year-end 2026, which could support accelerated approval [2][5]. - The ASPENOVA Phase 3 trial is set to initiate in the first half of 2026, comparing azenosertib to standard chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer (PROC) patients [2][5]. - Zentalis is also exploring azenosertib in combination with bevacizumab in the ongoing MUIR study for earlier treatment settings in ovarian cancer [2][5]. Product Information - Azenosertib is a selective, orally bioavailable WEE1 inhibitor that targets the G1-S and G2-M cell cycle checkpoints, potentially leading to cancer cell death by allowing cell cycle progression despite DNA damage [7][8]. - The drug is specifically being developed for Cyclin E1-positive PROC, a population that currently lacks approved treatment options, representing about 50% of PROC patients [8][9]. Upcoming Milestones - Key milestones for 2026 include dose confirmation for azenosertib monotherapy in Cyclin E1-positive PROC and the anticipated topline readout from the DENALI Part 2 trial [5][6].

Summary of Zentalis Pharmaceuticals Conference Call Company Overview - **Company**: Zentalis Pharmaceuticals (NasdaqGM:ZNTL) - **Focus**: Development of azenosertib, a Wee1 inhibitor targeting platinum-resistant ovarian cancer patients with high cyclin E1 expression [4][5] Key Developments - **Current Trials**: - Enrolling in the DENALI Part 2 trial, aimed at accelerated approval [4] - Completed enrollment in the first portion of DENALI trial, comparing 300 mg and 400 mg doses [5] - Initiating Phase 3 confirmatory study named ASPENOVA to support accelerated approval [5][62] Clinical Context - **Standard of Care for Platinum-Resistant Ovarian Cancer (PROC)**: - Current treatments yield response rates of 4%-13% with minimal progression-free survival (PFS) benefits [10] - Notable competitor, mirvetuximab, shows response rates around 30% with a duration of response of 5-6 months [11] Clinical Data and Expectations - **Response Rates**: - Zentalis aims for an overall response rate (ORR) of about 30% or higher, with a duration of response between 5-6 months [14][51] - Historical data from DENALI Part 1b shows a response rate in the low 30s% for cyclin E1 positive patients [20] - **Patient Population**: - Focus on patients with 1-3 prior lines of therapy, specifically those with cyclin E1 high expression [32] Trial Design and Regulatory Strategy - **ASPENOVA Trial**: - Randomized controlled trial designed to gather data on cyclin E1 patients against current standard care [66] - Adaptive design allows for early initiation and flexibility based on DENALI trial outcomes [63][66] - **Sample Size**: - ASPENOVA aims to enroll 420-450 patients [78] Future Directions - **MIRROR Study**: - Planned trial to explore combinations of azenosertib with bevacizumab in earlier lines of therapy for patients who progressed on PARP inhibitors [82][84] - Targeting a second-line maintenance setting with broad eligibility criteria [84] Market Position and Competitive Landscape - **Unmet Need**: - High unmet need in the PROC population, particularly for cyclin E1 high expression patients [10] - Zentalis positions azenosertib as a potential first-in-class treatment for this specific patient group [56] Additional Insights - **Regulatory Considerations**: - The FDA's evolving stance on accelerated approvals may allow for more flexibility in trial enrollment and data requirements [71][77] - **Patient Characteristics**: - The trial will include a mix of HRD positive and negative patients, with a focus on those who have progressed on prior therapies [86][88] This summary encapsulates the key points discussed during the conference call, highlighting Zentalis Pharmaceuticals' strategic focus, clinical developments, and market positioning in the oncology space.

Summary of Zentalis Pharmaceuticals FY Conference Call Company Overview - **Company**: Zentalis Pharmaceuticals (NasdaqGM:ZNTL) - **Focus**: Development of azenosertib, an oral non-chemotherapy treatment for biomarker-selected cancer patients Key Points Clinical Data and Treatment Efficacy - Azenosertib has shown a response rate over 30% and a duration of response of approximately 6 months in clinical trials, which is significantly better than single-agent chemotherapy with low double-digit response rates and short duration [2][3] - Over 500 patients have been treated with azenosertib, either as a monotherapy or in combination, demonstrating clear activity in patients who have failed other treatment options [4] - The DENALI trial is a multi-stage clinical program aimed at potential accelerated approval for azenosertib in PROTAC Cyclin E1-positive patients, with enrollment ongoing and expected to complete by year-end [5][6] Regulatory Pathway and FDA Interaction - The FDA has provided guidance on the accelerated approval pathway, emphasizing the need for a confirmatory randomized trial alongside the DENALI trial [9][10] - The ASPENOVA trial, a Phase 3 confirmatory study against single-agent chemotherapy, is designed to support full approval in the same patient population [5][6] Competitive Landscape - There is increasing competition in the market, particularly from antibody-drug conjugates (ADCs) targeting Folate receptor alpha, which may work regardless of biomarkers [7] - Azenosertib is positioned as a non-chemotherapy option that offers convenience and improved quality of life for patients, as it is an oral treatment compared to traditional IV chemotherapy [11][13] Biomarker Significance - Cyclin E1 overexpression is being studied as a biomarker for patient selection, with both gene amplification and high protein expression correlating to treatment response [29][30] - The DENALI trial includes prospective screening to validate the biomarker, with a focus on ensuring that patients who could benefit are not missed [34] Safety and Tolerability - Azenosertib is considered to have a manageable and well-tolerated safety profile compared to alternatives, with low discontinuation rates due to adverse events [46][48] - The trial management approach has been refined to enhance patient safety and support, which is expected to improve outcomes [39][40] Future Expectations - The company anticipates that the data from the ongoing trials will support the efficacy and safety of azenosertib, potentially leading to improved outcomes compared to previous trials [35][39] - The ASPENOVA trial design is similar to the successful MIRASOL trial, with an adaptive dose randomization to accelerate the process [50] Conclusion - Zentalis Pharmaceuticals is positioned for a pivotal year with the ongoing trials of azenosertib, which could provide a significant advancement in treatment options for patients with specific cancer biomarkers, while also addressing the need for more convenient and less toxic therapies [54]

Summary of Zentalis Pharmaceuticals Conference Call Company Overview - **Company**: Zentalis Pharmaceuticals (NasdaqGM:ZNTL) - **Focus**: Development of azenosertib for platinum-resistant ovarian cancer patients with high Cyclin E1 expression Key Strategic Priorities - **Primary Goal**: Accelerate the development of azenosertib, focusing on patients with platinum-resistant ovarian cancer and high Cyclin E1 expression [4][6] - **Current Trials**: - **DENALI Trial**: Multi-part registration trial, currently in Part 2A with 60 patients enrolled [12][13] - **ASPENOVA Trial**: Phase 3 randomized trial expected to enroll patients in the first half of the year [4][13] Competitive Landscape - **Market Dynamics**: Increasing competition in the platinum-resistant ovarian cancer space, particularly from antibody-drug conjugates (ADCs) [5] - **Differentiation of Azenosertib**: - Oral administration versus infusion for ADCs - Non-chemotherapy option providing a "chemo break" for patients [6][7] Clinical Profile and Tolerability - **Tolerability Data**: - Azenosertib shows a manageable tolerability profile with 10% high-grade neutropenia and low-grade gastrointestinal adverse events [10][11] - Comparison with other WEE1 inhibitors indicates a favorable safety profile [9][10] - **Dose Selection**: - Ongoing evaluation of 300 mg and 400 mg doses in DENALI, with a decision expected in the first half of the year [12][13][17] Biomarker and Patient Selection - **Cyclin E1 Expression**: Approximately 50% of patients in the PROC population are expected to meet the eligibility criteria based on Cyclin E1 expression [27] - **Eligibility Changes**: Part 2 of DENALI has stricter eligibility criteria compared to Part 1, focusing on patients with fewer prior lines of treatment [22] Regulatory Considerations - **Accelerated Approval Metrics**: - Expected overall response rate (ORR) of around 30% and median duration of response of 5-6 months for accelerated approval [48][49] - **ASPENOVA Design**: Randomized controlled trial against standard-of-care, with a focus on the same patient population as DENALI [31][39] Future Opportunities - **Combination Therapies**: Potential for azenosertib to be used in combination with other therapies, including cytotoxic agents and ADCs [50] - **Long-term Strategy**: Zentalis may explore additional assets post-azenosertib, contingent on successful proof of concept [58] Other Important Insights - **USC Study**: Fully enrolled with plans to provide data, but not a top priority for the company [51][56] - **Market Positioning**: Zentalis aims to prioritize ovarian cancer indications while keeping options open for future developments [58]

Core Insights - Zentalis Pharmaceuticals is advancing the late-stage development of its first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment for ovarian cancer [1][3] - The management team will participate in a fireside discussion at Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11 in New York [1] Company Overview - Zentalis Pharmaceuticals focuses on developing innovative oncology treatments, particularly for ovarian cancer and various tumor types [3] - The company aims to provide a targeted, non-chemotherapy, orally available medicine that enhances treatment experience and outcomes for cancer patients [3] Event Information - A live webcast of the upcoming event will be available for at least 30 days after the event concludes, accessible under the "Events & Presentations" tab on the company's website [2]

Summary of Zentalis Pharmaceuticals Conference Call Company Overview - **Company**: Zentalis Pharmaceuticals (NasdaqGM:ZNTL) - **Lead Candidate**: Azenosertib, an orally available non-chemotherapy treatment for Cyclin E1-positive platinum-resistant ovarian cancer [2][3] Industry Context - **Market Need**: High unmet need in the PROC (platinum-resistant ovarian cancer) setting, with no approved therapies for patients with Cyclin E1 overexpression [8][11] - **Current Standard of Care**: Single-agent chemotherapy with response rates between 4% and 13% [11] Key Points on Azenosertib - **Efficacy**: - Response rates over 30% and duration of response exceeding six months at a dose of 400 mg [3][12] - Over 350 patients treated at doses of 300 mg and above, with over 200 in the PROC setting [3] - **Safety Profile**: Manageable safety profile with tolerability comparable between 300 mg and 400 mg doses [4][12] - **Biomarker Development**: Companion diagnostic developed to identify patients for enrollment in trials [9][32] Clinical Trials - **Denali Trial**: - Part 2 designed for registration and accelerated approval pathway [5][14] - Focus on patients with one to three prior lines of therapy [14] - Expected top-line data by the end of 2026 [17][18] - **Phase 3 Trial**: Planned concurrent enrollment with Denali Part 2B, aiming for at least 80% enrollment for accelerated approval [16][25] Market Opportunity - **Patient Population**: Approximately 21,500 patients in the PROC setting with Cyclin E1 overexpression, representing about 50% of the market [8][10] - **Financial Potential**: Comparison to Elahere, which generated over $330 million in sales in the first half of the year, indicating strong market demand for biomarker-selected therapies [10] Competitive Landscape - **Other Treatments**: Acknowledgment of competition from antibody-drug conjugates (ADCs) and CDK2 inhibitors [26][27] - **Differentiation**: Azenosertib offers a non-chemotherapy option for patients who have had limited success with existing treatments [27][34] Regulatory and Development Strategy - **FDA Interaction**: Ongoing discussions with the FDA regarding trial design and accelerated approval pathways [15][24] - **Funding**: Cash runway supports development through late 2027, ensuring continued progress towards trial milestones [19] Conclusion - Zentalis Pharmaceuticals is focused on addressing a significant unmet need in the treatment of platinum-resistant ovarian cancer with azenosertib, leveraging a strong clinical development strategy and a clear understanding of the patient population and market dynamics [18][19]

Core Insights - Zentalis Pharmaceuticals has initiated dosing for the first patient in Part 2 of the Phase 2 DENALI clinical trial for azenosertib, targeting Cyclin E1+ platinum-resistant ovarian cancer [1][3] - The company anticipates topline data from DENALI Part 2 by the end of 2026, which could support accelerated approval from the FDA [2][3] - Azenosertib is a novel WEE1 inhibitor being evaluated as a monotherapy and in combination therapies across multiple tumor types [5][6] Clinical Trial Details - The DENALI trial is designed in two parts, with seamless enrollment; Part 2a aims to confirm the primary dose of azenosertib with approximately 30 patients at two dose levels: 400mg QD 5:2 and 300mg QD 5:2 [7] - Part 2b will enroll around 70 additional patients based on the results from Part 2a, pending FDA feedback [7] Clinical Data and Biomarkers - Previous data from Part 1b of the DENALI study indicated an objective response rate (ORR) of 34.9% among 43 response-evaluable patients, with a median duration of response (mDOR) of 6.3 months [3][4] - Cyclin E1 protein overexpression has been identified as a predictive biomarker for patient selection, with an estimated 50% of PROC patients overexpressing this protein [4] Company Overview - Zentalis Pharmaceuticals is focused on developing azenosertib as a potentially first-in-class and best-in-class treatment for Cyclin E1+ PROC, with ongoing research into additional applications [6] - The company has demonstrated that azenosertib is well tolerated and shows anti-tumor activity across various tumor types [6]

Core Insights - Zentalis Pharmaceuticals has reported positive clinical data for azenosertib, a WEE1 inhibitor, showing meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) [1][2] - The company anticipates topline data from the registration-intent DENALI Part 2 study by the end of 2026 [1][3] - Zentalis has strengthened its management team to support its focused strategy and has a cash position projected to last into late 2027 [1][2] Clinical Development - Updated clinical data from the DENALI Part 1b study showed an objective response rate (ORR) of 34.9% in patients with Cyclin E1+ PROC tumors, with a median duration of response (mDOR) of 6.3 months as of January 13, 2025 [3] - In the MAMMOTH study, Cyclin E1+ patients treated with azenosertib had an ORR of 31.3% and an mDOR of 4.2 months [3] - The ZN-c3-001 Phase 1 study reported an ORR of 34.8% and an mDOR of 5.2 months for patients treated with azenosertib [3] - The company has aligned with the FDA on the study design for DENALI Part 2, which will begin enrollment in the first half of 2025 [3] Financial Performance - As of December 31, 2024, Zentalis had cash, cash equivalents, and marketable securities totaling $371.1 million, sufficient to fund operations into late 2027 [1][5] - Research and development expenses for 2024 were $167.8 million, a decrease from $189.6 million in 2023, primarily due to reduced personnel expenses [5][12] - General and administrative expenses increased to $87.1 million in 2024 from $64.4 million in 2023, largely due to higher personnel costs [5][12] Corporate Updates - The company received Fast Track Designation from the FDA for azenosertib for treating PROC patients who are Cyclin E1 positive [4][6] - A strategic restructuring was announced in January 2025 to enhance efficiency in clinical development, which is expected to be completed by the second quarter of 2025 [4][6] - Zentalis has continued patient enrollment in various clinical trials, including studies for uterine serous carcinoma and in combination with bevacizumab [4][6]